Phase‑3 trial shows solengeprase cuts daily “off” time for Parkinson’s patients
In a 12‑week Phase 3 study, the experimental pill solengeprase reduced daily off‑time by up to 37 minutes and added roughly 36 minutes of dyskinesia‑free movement.
In a 12‑week Phase 3 study, the experimental pill solengeprase reduced daily off‑time by up to 37 minutes and added roughly 36 minutes of dyskinesia‑free movement.